Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 734,400 shares, an increase of 9.8% from the March 15th total of 669,100 shares. Based on an average trading volume of 200 shares, the days-to-cover ratio is presently 3,672.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

OTCMKTS:BIOVF opened at $25.00 on Wednesday. The stock has a fifty day moving average price of $25.59 and a 200-day moving average price of $24.04. The company has a market cap of $7.38 billion, a price-to-earnings ratio of 34.72 and a beta of 0.49. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.46 and a current ratio of 0.66. Swedish Orphan Biovitrum AB has a fifty-two week low of $18.35 and a fifty-two week high of $27.79.

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) last released its earnings results on Thursday, February 8th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.26). The company had revenue of $643.39 million for the quarter, compared to the consensus estimate of $668.74 million. Swedish Orphan Biovitrum AB (publ) had a net margin of 10.95% and a return on equity of 8.93%.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.